Here's some rough translations of data from Germany as published in Paul-Ehrlich-Institut vaccine safety reports . Unfortunately there's no data of CVST cases from the covid infected groups, only from the vaccinated group.

According to the Robert Koch Institute, 14,381,068 vaccinations had been performed by April 2, 2021, including 10,722,876 vaccinations with Comirnaty, 713,067 vaccinations with Moderna, and 2,945,125 vaccinations with Vaxzevria.

As of 04/02/2021, 42 cases of central venous/sinus vein thrombosis have been reported following vaccination with Vaxzevria. Thrombocytopenia was also reported in 23 cases.

All but seven of the other cases involved women aged 20 to 63 years. The men were aged 24 to 58 years. Eight patients (5 women, 3 men) died.

The Paul Ehrlich Institute has numerically more case reports of sinus vein thrombosis after vaccination with Vaxzevria in women (83.3% vs. 16.7%), with young women being particularly frequently affected. However, women were also vaccinated more frequently than men, according to the Robert Koch Institute.

For women aged 20-59 years, significantly more cases were observed (n=33) than would have been expected based on the background incidence.

Seven cases of sinus vein thrombosis were reported after vaccination with Comirnaty. No cases reported thrombocytopenia. Three women aged 34 to 81 years and four men aged 81 to 86 years were affected. The number of reported cases, taking into considering the doses inoculated compared with the expected Number of sinus thromboses not increased.

(Standardised Morbidity Ratio, SMR, 23.57; 95% CI: 16.22-33.10). The same was true for men aged 20-59 years (SMR 27.20; 95% CI: 10,94-56,04).